Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Privacy Policy

Thank you for visiting the Avalanche Biotechnologies website and for reviewing our privacy policy. The following statement explains our policy regarding personal information you may supply when visiting our website: Avalanche Biotechnologies does not sell, rent, or share information with any other organization. We do not transfer information for any promotional or marketing purposes, nor is that information shared with any third parties whatsoever. Our website contains links to other sites. We are not responsible for the privacy practices of these websites.

Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

MENLO PARK, Calif., Nov. 20, 2015 -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.

Read More

Read All Avalanche News